Magnus Financial Group LLC Buys New Position in Danaher Co. (NYSE:DHR)

Magnus Financial Group LLC bought a new stake in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 837 shares of the conglomerate’s stock, valued at approximately $233,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of DHR. Vanguard Group Inc. increased its holdings in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Swedbank AB purchased a new stake in Danaher during the 1st quarter worth approximately $676,545,000. TD Asset Management Inc increased its holdings in Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after purchasing an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Danaher by 22.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after purchasing an additional 563,546 shares during the last quarter. Finally, Castle Hook Partners LP purchased a new stake in Danaher during the 1st quarter worth approximately $98,913,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners boosted their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Finally, Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Trading Down 1.7 %

Shares of DHR stock opened at $267.99 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The stock has a fifty day moving average of $270.53 and a two-hundred day moving average of $259.65. The firm has a market capitalization of $198.50 billion, a PE ratio of 45.42, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.